Alberto Santagostino appointed new CEO of MVA member AGC Biologics

Monday this week AGC Biologics announced the appointment of Alberto Santagostino to Chief Executive Officer and President of AGC Biologics, effective November 1st. Alberto has had a distinguished career in biotech, pharma and managing large-scale global CDMO operations most recently as Head of Cell and Gene Technology with from another MVA member company, Lonza. His expertise and knowledge will lead AGC Biologics’ next chapter as the company reemphasizes delivering reliable services to biopharmaceutical developers without unnecessary complications. “I am excited to announce Alberto is joining us to lead AGC Biologics and to set the tone for the coming years. We share the common vision of service, delivery and quality that is at the core of AGC Group’s business philosophy,” said Tadashi Murano, President of AGC Life Science Company, “I am confident Alberto will bring both a wide knowledge of the biopharma industry and the experience of successfully leading growth at scale. He will enhance AGC Biologics’ reputation as an increasingly preferable CDMO in the industry.” Read full press release online.